CN114302738A - 减毒登革病毒 - Google Patents

减毒登革病毒 Download PDF

Info

Publication number
CN114302738A
CN114302738A CN202080060629.9A CN202080060629A CN114302738A CN 114302738 A CN114302738 A CN 114302738A CN 202080060629 A CN202080060629 A CN 202080060629A CN 114302738 A CN114302738 A CN 114302738A
Authority
CN
China
Prior art keywords
protein
dengue virus
coding sequence
less
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080060629.9A
Other languages
English (en)
Chinese (zh)
Inventor
斯特芬·穆勒
约翰·罗伯特·科尔曼
查尔斯·斯塔夫
王颖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kodak Jinnix Co ltd
Original Assignee
Kodak Jinnix Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kodak Jinnix Co ltd filed Critical Kodak Jinnix Co ltd
Publication of CN114302738A publication Critical patent/CN114302738A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN202080060629.9A 2019-06-25 2020-06-23 减毒登革病毒 Pending CN114302738A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962866477P 2019-06-25 2019-06-25
US62/866,477 2019-06-25
PCT/US2020/039166 WO2020263850A1 (en) 2019-06-25 2020-06-23 Attenuated dengue viruses

Publications (1)

Publication Number Publication Date
CN114302738A true CN114302738A (zh) 2022-04-08

Family

ID=74060347

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080060629.9A Pending CN114302738A (zh) 2019-06-25 2020-06-23 减毒登革病毒

Country Status (16)

Country Link
US (1) US20220347285A1 (https=)
EP (2) EP3990014A4 (https=)
JP (2) JP2022540773A (https=)
CN (1) CN114302738A (https=)
AU (1) AU2020307532A1 (https=)
BR (1) BR112021026201A8 (https=)
CA (1) CA3145401A1 (https=)
CL (1) CL2021003475A1 (https=)
CO (1) CO2021017772A2 (https=)
CR (1) CR20210677A (https=)
DO (1) DOP2021000271A (https=)
IL (1) IL289274A (https=)
MX (1) MX2022000038A (https=)
PE (1) PE20220296A1 (https=)
PH (1) PH12021553305A1 (https=)
WO (1) WO2020263850A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119899808A (zh) * 2024-12-05 2025-04-29 深圳湾实验室 登革减毒株及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12178869B2 (en) 2017-12-22 2024-12-31 Codagenix Inc. Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
WO2019172982A1 (en) 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190002837A1 (en) * 2014-09-05 2019-01-03 The Research Foundation For The State University Of New York Recoded arbovirus and vaccines
CN109152828A (zh) * 2016-03-11 2019-01-04 美国政府(由卫生和人类服务部的部长所代表) 减毒活zika病毒疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2587084C (en) * 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
KR101621100B1 (ko) 2007-03-30 2016-05-13 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 백신에 유용한 약독화 바이러스
US20120269849A1 (en) 2009-10-09 2012-10-25 Eckard Wimmer Attenuated influenza viruses and vaccines
JP2016523251A (ja) * 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． デングウイルスワクチン組成物およびその使用方法
US11111481B2 (en) * 2015-09-30 2021-09-07 Ramot At Tel-Aviv University Ltd. Attenuated virus mutated at sites of evolutionarily conserved RNA structure
WO2019172982A1 (en) * 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190002837A1 (en) * 2014-09-05 2019-01-03 The Research Foundation For The State University Of New York Recoded arbovirus and vaccines
CN109152828A (zh) * 2016-03-11 2019-01-04 美国政府(由卫生和人类服务部的部长所代表) 减毒活zika病毒疫苗

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SAM H. SHEN 等: ""Large-scale recoding of an arbovirus genome to rebalance its insect versus mammalian preference"", 《PNAS》, vol. 112, no. 15, pages 4749, XP055451303, DOI: 10.1073/pnas.1502864112 *
SUSANTA K BEHURA 等: ""Nucleotide substitutions in dengue virus serotypes from Asian and American countries: Insights into intracodon recombination and purifying selection"", 《BEHURA AND SEVERSON BMC MICROBIOLOGY》, vol. 13, no. 37, pages 1 - 13 *
曾睿 等: ""登革热疫苗的研究进展"", 《预防医学论坛》, vol. 23, no. 10, pages 796 - 799 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119899808A (zh) * 2024-12-05 2025-04-29 深圳湾实验室 登革减毒株及其应用

Also Published As

Publication number Publication date
PH12021553305A1 (en) 2022-08-01
CL2021003475A1 (es) 2023-01-06
IL289274A (en) 2022-02-01
CR20210677A (es) 2022-04-26
MX2022000038A (es) 2022-02-24
WO2020263850A1 (en) 2020-12-30
EP3990014A1 (en) 2022-05-04
CA3145401A1 (en) 2020-12-30
BR112021026201A8 (pt) 2022-05-10
BR112021026201A2 (pt) 2022-02-15
CO2021017772A2 (es) 2022-04-19
JP2022540773A (ja) 2022-09-20
US20220347285A1 (en) 2022-11-03
DOP2021000271A (es) 2022-04-18
JP2025041836A (ja) 2025-03-26
AU2020307532A1 (en) 2022-01-27
PE20220296A1 (es) 2022-03-07
EP4707387A2 (en) 2026-03-11
EP3990014A4 (en) 2023-11-22

Similar Documents

Publication Publication Date Title
AU2018267542B2 (en) Compositions And Methods Of Vaccination Against Dengue Virus In Children And Young Adults
CN101238209B (zh) 登革血清型2减毒株
AU2019216724C1 (en) Compositions and methods for dengue virus chimeric constructs in vaccines
JP4977811B2 (ja) デング熱１、２、３および４型又は抗原性キメラデング熱ウイルス１、２、３および４の３’−ｕｔｒにおいて３０ヌクレオチド欠失を共通に含有するデング熱四価ワクチン
CN101553251B (zh) 针对4种登革热血清型的免疫方法
KR101464649B1 (ko) 약독화된 뎅기 혈청형 1 균주
JP2025041836A (ja) 弱毒化デングウイルス
KR20090027759A (ko) 뎅기열의 4 가지 혈청형에 대한 면역화 방법
US12168049B2 (en) Attenuated flaviviruses
KR20180127397A (ko) 생약독화된 지카 바이러스 백신

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220408